Markos Kalligeros

Dr. Markos Kalligeros

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MKMarkos Kalligeros
Markos Kalligeros
AVAthanasios Vassilopoulos
Athanasios Vassilopoulos
SVStephanos Vassilopoulos
Stephanos Vassilopoulos
DVDavid W. Victor
David W. Victor
EMEleftherios Mylonakis
Eleftherios Mylonakis
MNMazen Noureddin
Mazen Noureddin

13 January 2023 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
MKMarkos Kalligeros
Markos Kalligeros
AVAthanasios Vassilopoulos
Athanasios Vassilopoulos
FSFadi Shehadeh
Fadi Shehadeh
SVStephanos Vassilopoulos
Stephanos Vassilopoulos
ILIngrid Lazaridou
Ingrid Lazaridou
JWJack R. Wands
Jack R. Wands

17 September 2020 in Pathogens
Verified
Journal Article
Open access
PDF file
SSSophia Song
Sophia Song
SHSarah B. Hays
Sarah B. Hays
CPConstance E. Panton
Constance E. Panton
EMEvangelia K. Mylona
Evangelia K. Mylona
MKMarkos Kalligeros
Markos Kalligeros
Eleftherios MylonakisEleftherios Mylonakis
Eleftherios Mylonakis
COVID-19 disproportionately affects patients with medical comorbidities such as cardiovascular disease (CVD). Patients with CVD are widely prescribed 3-hydroxy-3-methyl-glutayl-CoA (HMG-CoA) reductase inhibitors (statins), a class of lipid-lowering medications known for their pleiotropic anti-inflammatory and immunomodulatory effects. However, the relationship between statin use and COVID-19 outcomes is not fully understood. In this preliminary study, we explored the association between statin use and severe COVID-19 outcomes in hospitalized patients, including intensive care unit (ICU) admission, the need for invasive mechanical ventilation (IMV), and in-hospital death. We performed a retrospective cohort study of 249 patients hospitalized with COVID-19 from 3 March 2020 to 10 April 2020 in Rhode Island, USA. Patient demographics, past medical history, current medications, and hospital course were recorded and analyzed. A multivariate logistic regression analysis was conducted to examine associations. After adjusting for age, sex, race, cardiovascular disease, chronic pulmonary disease, diabetes, and obesity, statin use was significantly associated with decreased risk for IMV (adjusted Odds Ratio (aOR) = 0.45, 95% Confidence Interval (CI): 0.20–0.99). Our results support the continued use of statins among COVID-19 patients and could have implications for future prospective studies on the management of COVID-19.

1 March 2020 in The American Journal of Medicine
Verified
Journal Article
Closed access
Eleftherios MylonakisEleftherios Mylonakis
Eleftherios Mylonakis
FSFadi Shehadeh
Fadi Shehadeh
EFElvira Fleury
Elvira Fleury
MKMarkos Kalligeros
Markos Kalligeros
Eleftherios MylonakisEleftherios Mylonakis
Eleftherios Mylonakis

SMSophia C. Mylonakis
Sophia C. Mylonakis
EMEvangelia K. Mylona
Evangelia K. Mylona
MKMarkos Kalligeros
Markos Kalligeros
FSFadi Shehadeh
Fadi Shehadeh
PCPhilip A. Chan
Philip A. Chan
Eleftherios MylonakisEleftherios Mylonakis
Eleftherios Mylonakis
Influenza is a contagious respiratory illness and can lead to hospitalization and even death. Understanding how comorbidities affect the severity of influenza can help clinical management. The aim of this study is to offer more information about comorbidities that might be associated with the severity of influenza in children. We used a statewide network in Rhode Island, USA, to extract data for laboratory-confirmed influenza cases among children 19 years old or younger. We identified 1169 lab-confirmed influenza cases. The most common comorbidities were asthma (17.1%), neurodevelopmental disorders (10.3%), gastrointestinal disorders (7.6%), atopic dermatitis (7%), and endocrine and metabolic diseases (6.8%). Interestingly, 80.8% (63 out of 78) of children who had an influenza-related hospital admission had at least one comorbidity, and among hospitalized children with influenza, the most common comorbidities were neurological diseases (28.2%, 22/78), gastrointestinal disorders (25.6%, 20/78), endocrine and metabolic diseases (24.4%, 19/78), and neurodevelopmental disorders (23.1%, 18/78). Children with endocrine or metabolic diseases were 8.23 times more likely to be admitted to the hospital, and children with neurological disorders were 6.35 times more likely to be admitted (OR: 8.23, 95% CI: 4.42–15.32 and OR: 6.35, 95% CI: 3.60–11.24, respectively). In summary, we identified specific comorbidities associated with influenza hospitalization and length of hospital stay, and these groups should be prioritized for public health interventions.

5 January 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDPojsakorn Danpanichkul
Pojsakorn Danpanichkul
KDKwanjit Duangsonk
Kwanjit Duangsonk
MKMarkos Kalligeros
Markos Kalligeros
MFMichael B. Fallon
Michael B. Fallon
CVChawinthorn Vuthithammee
Chawinthorn Vuthithammee
KWKarn Wijarnpreecha
Karn Wijarnpreecha